scbmtБИОМЕДИЦИНАJournal Biomed2074-59822713-0428Scientific center of biomedical technologies of Federal Medical and Biological Agency10.33647/2713-0428-19-3E-77-80scbmt-1514Research ArticleМЕТОДЫ И ТЕХНОЛОГИИ БИОМЕДИЦИНСКИХ ИССЛЕДОВАНИЙMETHODS AND TECHNOLOGIES OF BIOMEDICAL RESEARCHИзучение влияния гепарина на взаимодействие антиген-антитело в модельной системе терапевтического антитела бевацизумаб и его мишени VEGF-А165Effect of Heparin on Antigen-Antibody Interaction in a Model System of the Bevacizumab Therapeutic Antibody And its Target VEGF-А165ШевелёваМ. П.ShevelyovaM. P.

Шевелёва Марина Петровна - кандидат химических наук.

142290, Московская обл., Пущино, просп. Науки, 3

Marina P. Shevelyova - Cand. Sci. (Chem.)

142290, Moscow Region, Pushchino, Nauki Ave., 3

marina.shevelyova@gmail.comНемашкаловаЕ. Л.NemashkalovaE. L.

Немашкалова Екатерина Леонидовна - кандидат биологических наук.

142290, Московская обл., Пущино, просп. Науки, 3

Ekaterina L. Nemashkalova - Cand. Sci. (Biol.)

142290, Moscow Region, Pushchino, Nauki Ave., 3

elnemashkalova@gmail.comДерюшеваЕ. И.DeryushevaE. I.

Дерюшева Евгения Игоревна - кандидат физико-математических наук.

142290, Московская обл., Пущино, просп. Науки, 3

Evgeniya I. Deryusheva - Cand. Sci. (Phis.-Math.)

142290, Moscow Region, Pushchino, Nauki Ave., 3

evgenia.deryusheva@gmail.comИнститут биологического приборостроения ФГБУН ФИЦ «Пущинский научный центр биологических исследований» РАНРоссияInstitute for Biological Instrumentation of the Pushchino Scientific Center for Biological Research of the Russian Academy of SciencesRussian Federation202320112023193E7780Copyright © Шевелёва М.П., Немашкалова Е.Л., Дерюшева Е.И., 20232023Шевелёва М.П., Немашкалова Е.Л., Дерюшева Е.И.Shevelyova M.P., Nemashkalova E.L., Deryusheva E.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.scbmt.ru/jour/article/view/1514

В данной работе проведено исследование влияния гепарина на процесс связывания VEGF-A165 — наиболее распространенного и важного из факторов роста — и моноклонального антитела бевацизумаб методом биослойной интерферометрии. Смоделирован комплекс полноразмерного антитела бевацизумаб с VEGF-A165. Полученные данные можно использовать при терапии с использованием данного антитела, а также в разработке других терапевтических антител c максимальной специфичностью к мишеням в различных условиях.

In this work, we studied the effect of heparin on the binding process of VEGF-A165, the most common and important growth factor, and the monoclonal antibody bevacizumab by bio-layer interferometry. A complex of the full-length bevacizumab antibody with VEGF-A165 was modeled. The data obtained can be used in therapy with this antibody, as well as in the development of other therapeutic antibodies with maximum target specificity under various conditions.

фактор роста эндотелия сосудов (VEGF)бевацизумабгепаринvascular endothelial growth factor (VEGF)bevacizumabheparinисследование выполнено при финансовой поддержке Российского научного фонда, грант № 22-24-00083research was funded by a grant from the Russian Science Foundation No. 22-24-00083ReferencesAdamis A.P., Shima D.T. The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005;25:111–118. DOI: 10.1097/00006982-200502000-00001.Adamis A.P., Shima D.T. The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005;25:111–118. DOI: 10.1097/00006982-200502000-00001.Apte R.S., Chen D.S., Ferrara N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019;176:1248–1264. DOI: 10.1016/j.cell.2019.01.021.Apte R.S., Chen D.S., Ferrara N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019;176:1248–1264. DOI: 10.1016/j.cell.2019.01.021.Engelberg H. Plasma heparin levels in normal man. Circulation. 1961;23:578–581. DOI: 10.1161/01.cir.23.4.578.Engelberg H. Plasma heparin levels in normal man. Circulation. 1961;23:578–581. DOI: 10.1161/01.cir.23.4.578.Ferrara N. VEGF-A: A critical regulator of blood vessel growth. Eur. Cytokine Netw. 2009;20:158–163. DOI: 10.1684/ecn.2009.0170.Ferrara N. VEGF-A: A critical regulator of blood vessel growth. Eur. Cytokine Netw. 2009;20:158–163. DOI: 10.1684/ecn.2009.0170.Garcia J., Hurwitz H.I., Sandler A.B., Miles D., Coleman R.L., Deurloo R., Chinot O.L. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat. Rev. 2020;86:102017. DOI: 10.1016/j.ctrv.2020.102017.Garcia J., Hurwitz H.I., Sandler A.B., Miles D., Coleman R.L., Deurloo R., Chinot O.L. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat. Rev. 2020;86:102017. DOI: 10.1016/j.ctrv.2020.102017.Gitay-Goren H., Soker S., Vlodavsky I., Neufeld G. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated hep-arin-like molecules. J. Biol. Chem. 1992;267:6093–6098. DOI: 10.1016/S0021-9258(18)42666-X.Gitay-Goren H., Soker S., Vlodavsky I., Neufeld G. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated hep-arin-like molecules. J. Biol. Chem. 1992;267:6093–6098. DOI: 10.1016/S0021-9258(18)42666-X.Keyt B.A., Berleau L.T., Nguyen H.V., Chen H., Heinsohn H., Vandlen R., Ferrara N. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J. Biol. Chem. 1996;271:7788–7795. DOI: 10.1074/jbc.271.13.7788.Keyt B.A., Berleau L.T., Nguyen H.V., Chen H., Heinsohn H., Vandlen R., Ferrara N. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J. Biol. Chem. 1996;271:7788–7795. DOI: 10.1074/jbc.271.13.7788.Nemashkalova E.L., Shevelyova M.P., Machulin A.V., Lykoshin D.D., Esipov R.S., Deryusheva E.I. Heparin-Induced Changes of Vascular Endothelial Growth Factor (VEGF165) Structure. Biomolecules. 2023;13(1):98. DOI: 10.3390/biom13010098.Nemashkalova E.L., Shevelyova M.P., Machulin A.V., Lykoshin D.D., Esipov R.S., Deryusheva E.I. Heparin-Induced Changes of Vascular Endothelial Growth Factor (VEGF165) Structure. Biomolecules. 2023;13(1):98. DOI: 10.3390/biom13010098.Onishi A., Ange K.St., Dordick J.S., Linhardt R.J. Heparin and anticoagulation. Front. Biosci. (Landmark Ed.) 2016;21(7):1372–1392. DOI: 10.2741/4462.Onishi A., Ange K.St., Dordick J.S., Linhardt R.J. Heparin and anticoagulation. Front. Biosci. (Landmark Ed.) 2016;21(7):1372–1392. DOI: 10.2741/4462.Papadopoulos N., Martin J., Ruan Q., et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171–185. DOI: 10.1007/s10456-011-9249-6.Papadopoulos N., Martin J., Ruan Q., et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171–185. DOI: 10.1007/s10456-011-9249-6.

The authors declare that there are no conflicts of interest present.